KR102293847B1 - 근위축성 측색 경화증 환자 아집단의 치료를 위한 마시티닙의 용도 - Google Patents

근위축성 측색 경화증 환자 아집단의 치료를 위한 마시티닙의 용도 Download PDF

Info

Publication number
KR102293847B1
KR102293847B1 KR1020187026871A KR20187026871A KR102293847B1 KR 102293847 B1 KR102293847 B1 KR 102293847B1 KR 1020187026871 A KR1020187026871 A KR 1020187026871A KR 20187026871 A KR20187026871 A KR 20187026871A KR 102293847 B1 KR102293847 B1 KR 102293847B1
Authority
KR
South Korea
Prior art keywords
als
masitinib
alsfrs
points
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187026871A
Other languages
English (en)
Korean (ko)
Other versions
KR20180125966A (ko
Inventor
알랭 마우지
진-피에르 키넷
콜린 맨스필드
Original Assignee
에이비 사이언스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에이비 사이언스 filed Critical 에이비 사이언스
Publication of KR20180125966A publication Critical patent/KR20180125966A/ko
Application granted granted Critical
Publication of KR102293847B1 publication Critical patent/KR102293847B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020187026871A 2016-03-25 2017-03-24 근위축성 측색 경화증 환자 아집단의 치료를 위한 마시티닙의 용도 Active KR102293847B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16162490 2016-03-25
EP16162490.3 2016-03-25
PCT/EP2017/057134 WO2017162884A1 (en) 2016-03-25 2017-03-24 Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation

Publications (2)

Publication Number Publication Date
KR20180125966A KR20180125966A (ko) 2018-11-26
KR102293847B1 true KR102293847B1 (ko) 2021-08-26

Family

ID=55637258

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187026871A Active KR102293847B1 (ko) 2016-03-25 2017-03-24 근위축성 측색 경화증 환자 아집단의 치료를 위한 마시티닙의 용도

Country Status (20)

Country Link
US (1) US10092564B2 (cg-RX-API-DMAC7.html)
EP (1) EP3240538B1 (cg-RX-API-DMAC7.html)
JP (2) JP7250312B2 (cg-RX-API-DMAC7.html)
KR (1) KR102293847B1 (cg-RX-API-DMAC7.html)
CN (1) CN108883108B (cg-RX-API-DMAC7.html)
AU (1) AU2017236177B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018069515A2 (cg-RX-API-DMAC7.html)
CA (1) CA3018635C (cg-RX-API-DMAC7.html)
DK (1) DK3240538T3 (cg-RX-API-DMAC7.html)
EA (1) EA038531B1 (cg-RX-API-DMAC7.html)
ES (1) ES2899929T3 (cg-RX-API-DMAC7.html)
HU (1) HUE057398T2 (cg-RX-API-DMAC7.html)
IL (1) IL261856B (cg-RX-API-DMAC7.html)
MX (1) MX390495B (cg-RX-API-DMAC7.html)
NZ (1) NZ745778A (cg-RX-API-DMAC7.html)
PL (1) PL3240538T3 (cg-RX-API-DMAC7.html)
PT (1) PT3240538T (cg-RX-API-DMAC7.html)
SG (1) SG11201808106YA (cg-RX-API-DMAC7.html)
SI (1) SI3240538T1 (cg-RX-API-DMAC7.html)
WO (1) WO2017162884A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
CN104869993B (zh) 2012-10-25 2019-01-15 通用医疗公司 治疗阿尔茨海默病及相关疾病的组合疗法
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
AU2014340182B2 (en) 2013-10-22 2019-05-23 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
US20190240194A1 (en) * 2016-08-31 2019-08-08 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
MX379222B (es) 2016-11-25 2025-03-10 Genuv Inc Composición para promover la diferenciación y protección de células madre neurales y método para inducir la regeneración neural usando las mismas.
CA3057040A1 (en) * 2017-03-28 2018-10-04 Novartis Ag New methods for the treatment of multiple sclerosis
BR112019025346A2 (pt) * 2017-05-30 2020-06-30 Deciphera Pharmaceuticals, Inc. uso de 1-[4-bromo-5-[1-etil-7-(metilamino)-2-oxo-1,2-dihidro-1,6-naftiridin-3-il]-2-fluorofenil]-3-fenilureia e análogos para o tratamento de cânceres associados a anormalidades genéticas no receptor alfa do fator de crescimento derivado de plaquetas
US11692029B2 (en) 2018-03-05 2023-07-04 The Schepens Eye Research Institute, Inc. Therapy for glaucoma and optic neuropathy by targeting colony stimulating factors
KR20210071943A (ko) 2018-07-02 2021-06-16 더 제너럴 하스피탈 코포레이션 크로몰린 소듐 및 α-락토스의 분말화된 제형
US12383528B2 (en) 2018-12-10 2025-08-12 The General Hospital Corporation Cromolyn esters and uses thereof
CN112618717A (zh) * 2019-09-24 2021-04-09 北京大学深圳研究生院 Btk抑制剂用于治疗肌萎缩侧索硬化症的用途
FI4084779T3 (fi) * 2019-12-30 2024-12-16 Deciphera Pharmaceuticals Llc 1-(4-bromi-5-(1-etyyli-7-(metyyliamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yyli)-2-fluorifenyyli)-3-fenyyliurean koostumuksia
WO2021207060A1 (en) 2020-04-06 2021-10-14 The General Hospital Corporation Methods of treatment of coronavirus-induced inflammation conditions
US12612391B2 (en) 2020-12-28 2026-04-28 The General Hospital Corporation Cromolyn derivatives and uses thereof
US20250129067A1 (en) * 2021-11-08 2025-04-24 Progentos Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
WO2025113494A1 (zh) * 2023-11-27 2025-06-05 浙江径科医药有限公司 多环类化合物及其应用
WO2026015576A1 (en) * 2024-07-09 2026-01-15 PhenoNet, Inc. Methods and systems for treatment of neurodegenerative disease and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015063318A1 (en) 2013-11-04 2015-05-07 Ab Science Use of masitinib for treatment of amyotrophic lateral sclerosis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (cg-RX-API-DMAC7.html) 1992-04-03 1994-06-21 Ciba Geigy Ag
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
US8450302B2 (en) 2002-08-02 2013-05-28 Ab Science 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
MXPA05001277A (es) 2002-08-02 2005-10-06 Ab Science 2-(3-aminoaril)amino-4-aril-tiazoles y su uso como inhibidores del c-kit.
HRP20110709T1 (hr) 2007-02-13 2011-11-30 Ab Science Postupak sinteze spojeva 2-aminotioazola kao inhibitora kinaza
TW201204360A (en) 2010-04-20 2012-02-01 Ab Science Treatment of multiple sclerosis with MASITINIB
CN109316480A (zh) 2011-07-13 2019-02-12 赛特凯恩蒂克公司 组合als疗法
AU2013326463B2 (en) * 2012-10-04 2018-01-18 Ab Science Use of masitinib for treatment of cancer in patient subpopulations identified using predictor factors
EP2970317A4 (en) * 2013-03-15 2016-11-02 Dana Farber Cancer Inst Inc PYRIMIDODIAZEPINONE COMPOUNDS AND METHOD FOR THE TREATMENT OF DISEASES

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015063318A1 (en) 2013-11-04 2015-05-07 Ab Science Use of masitinib for treatment of amyotrophic lateral sclerosis

Also Published As

Publication number Publication date
EP3240538A1 (en) 2017-11-08
NZ745778A (en) 2022-07-01
WO2017162884A1 (en) 2017-09-28
US10092564B2 (en) 2018-10-09
CN108883108B (zh) 2021-08-06
CA3018635A1 (en) 2017-09-28
JP2019515884A (ja) 2019-06-13
IL261856B (en) 2022-04-01
MX2018011349A (es) 2019-02-07
CA3018635C (en) 2023-09-26
AU2017236177A1 (en) 2018-09-20
MX390495B (es) 2025-03-20
EA038531B1 (ru) 2021-09-10
PL3240538T3 (pl) 2022-01-31
SG11201808106YA (en) 2018-10-30
DK3240538T3 (da) 2021-12-06
US20180117037A1 (en) 2018-05-03
IL261856A (en) 2018-10-31
EA201800499A1 (ru) 2019-03-29
CN108883108A (zh) 2018-11-23
KR20180125966A (ko) 2018-11-26
PT3240538T (pt) 2021-12-07
EP3240538B1 (en) 2021-09-29
ES2899929T3 (es) 2022-03-15
BR112018069515A2 (pt) 2019-04-16
SI3240538T1 (sl) 2022-02-28
JP7250312B2 (ja) 2023-04-03
HUE057398T2 (hu) 2022-05-28
AU2017236177B2 (en) 2022-03-31
JP2022037132A (ja) 2022-03-08

Similar Documents

Publication Publication Date Title
EP3240538B1 (en) Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
US9078894B2 (en) Treatment of severe persistant asthma with masitinib
RU2672248C1 (ru) Применение производного бензимидазола для лечения ночного кислотного прорыва
KR20170122777A (ko) 트라디피턴트에 의한 치료 방법
US20140147415A1 (en) Treatment of mastocytosis with masitinib
US20170119760A1 (en) Use of masitinib for the treatment of progressive supranuclear palsy
US8513280B2 (en) Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
EP1496908B1 (en) Combination of glivec(sti571) with a cyclin-dependent kinase inhibitor, especially flavopiridol in the treatment of cancer
HK1261581B (en) Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
JP2019517516A (ja) Smaの新規な処置
HK1261581A1 (en) Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
EP4069230A1 (en) Use of masitinib for the treatment of eosinophilic asthma
WO2016071511A1 (en) Treatment of mast cell activation syndrome (mcas) with masitinib
US20230321081A1 (en) Masitinib for the treatment of castrate-resistant prostate cancer
JP6414727B2 (ja) 関節疾患の治療予防剤
JP2014532684A (ja) Vegf依存性疾患の治療に使用する2−カルボキサミドシクロアミノウレア誘導体

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5